Sanofi Announces New Executive VP of Diabetes and Cardiovascular
Sanofi has promoted Stefan Oelrich to the position of Executive Vice President of Diabetes and Cardiovascular, where he will solidify the company’s position in a highly competitive market. Oelrich had previously held the role as the Global Head of the Diabetes Franchise, as well as being the acting head of Diabetes and Cardiovascular in North America since July of this year.
“Stefan is a highly effective leader who has demonstrated his ability to deliver strong results during his tenure at Sanofi,” said Olivier Brandicourt, Sanofi’s Chief Executive Officer. Prior to joining Sanofi as General Manager of Germany, Switzerland, and Austria, Oelrich gained years of experience at Bayer, where he rose to Senior Vice President & General Manager of Women’s Healthcare.
Merck promotes New Head of MEA
Merck has promoted Paolo Carli to head of healthcare business for the Middle East, Africa, and Turkey (MEA) region. For four years previously, Carli was Managing Director of the Middle East and Egypt region and had been a part of Merck’s finance department for five years prior to this. He’s gained further experience as VP of Global Business Development at Deutsche Bank.
Carli is delighted about his promotion, commenting, “Being a strategic region for Merck, we are committed to excel innovation and create value for patients across this region. Our innovative treatment options and sustainable commitment for patients will move us to the next level.”
The full-service communications agency has made new hires to their rapidly expanding St. Louis office including Melinda Love, VP Client Engagement, and Mary Habermaas, Senior Digital Producer. Love oversees all 2e account services and is responsible for the health and direction of client business, while ensuring stellar client service. Love previously served as Senior Vice President, Senior Partner, and Senior Creative Director at FleishmanHillard. Habermaas was a Senior Digital Producer at HLK prior to joining 2e and will now be responsible for incorporating innovative technology and data to accelerate digital strategies and engage audiences.
The drug development company focused on co-development and financing of late-stage pharmaceutical candidates has appointed Kathryn J. Gregory as Chief Business Officer. Previously, she served in leadership positions at Purdue Pharma, Shire Pharmaceuticals (where she worked in the Neuroscience and Ophthalmology Business Units), and most recently, Seneb BioSciences.
Lars Bruening has been appointed the new CEO of Bayer UK and Ireland. Previously, he was head of the pharma group’s global market access business in Berlin. Bruening also held leadership positions in Europe, the Middle East, and Asia for Bayer where he gained necessary experience in the international healthcare landscape and global commercial markets.
The biotech company that builds a new breed of therapies from a bicyclic peptide has named Maria Koehler, MD, PhD, Chief Medical Officer. As an experienced oncologist, Dr. Koehler will lead clinical strategy and oversee operational functions for Bicycle’s clinical development team. She has more than 20 years of industry experience, most recently serving as VP of Strategy, Innovation, and Collaborations for the Oncology Business Unit for Pfizer.
CVC Capital Partners
Former Allergan executive, Anish Mehta, has been appointed as CEO of the international women’s health assets portfolio, which CVC will be acquiring from Teva. Previously, Mehta was Head of International Business Development at Allergan, and prior to this he served as head for the European and Middle East businesses at Actavis.
Andrew Hotchkiss has been appointed Chief Commercial Officer of the global company focused on developing biological drugs for cancer and autoimmune diseases. Hotchkiss joins Immunocore from Eli Lilly & Co. where he held a number of leadership positions.
Matt Giegerich will now serve as CEO for the agency’s two lead business units: Inception Digital, a virtual meetings technology company, and Kampfire, a video production company that creates compelling brand content to influence consumer behavior. He was previously CEO of WPP’s Ogilvy CommonHealth.
Former Genzyme CEO and Rhythm biotech Chairman, David Meeker, has emerged as CEO of the two-year-old KSQ Therapeutics. Meeker says he will utilize the CRISPRomics drug discovery engine to “focus on high-confidence, patient-tailored, novel drug candidates.”
Prime Global Group
The communications agency has appointed Victoria Boswell-Smith, PhD as VP of Client Services. She will head Core Medica Ltd. and Paragon Medica Ltd. and aid Onyx Ltd., the Group’s rare disease agency. Previously, Boswell-Smith served as Director of Medical Education Healthcare at 90TEN.
As the new Chief Scientist for Health with the Scottish Government, David Crossman will identify, promote, and encourage research to address the healthcare needs of Scotland. Most recently he served as Dean of Medicine at the University of St. Andrews.
The U.S. biotech company appointed Daniella Beckman to its Board of Directors. She boasts more than 15 years experience and currently provides consulting and interim CFO services for early-stage biotech companies, including Tango Therapeutics and Neon Therapeutics. Prior to this, she was CFO of Idenix Pharmaceuticals until Merck acquired it.
UDG Healthcare and Ashfield
Jez Moulding has been appointed Chief Operating Officer of UDG Healthcare and Executive Vice President of Ashfield. Moulding will be responsible for Group IT, Quality, Compliance, Strategy, and Communications. He previously spent 18 years in various global leadership positions at Sanofi, most recently serving as SVP and North America Region Head for Diabetes and Cardiovascular.